Zurcher Kantonalbank (Zurich Cantonalbank) Athira Pharma, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 09, 2022	SELL	$2.74 - $13.43 $528 - $2,591	-193 Reduced 8.11%	2,186 $7,000
Q1 2022 Apr 21, 2022	BUY	$8.96 - $13.51 $21,315 - $32,140	2,379 New	2,379 $32,000

Others Institutions Holding ATHA

# of Institutions

Shares Held

16.9M

Call Options Held

112K

Put Options Held

68K

Perceptive Advisors LLC New York, NY

5.4M
Shares

$3.51 Million
0.06% of portfolio
Vanguard Group Inc Valley Forge, PA

1.61M
Shares

$1.05 Million
0.0% of portfolio
Simplify Asset Management Inc. New York, NY

1.49M
Shares

$970,314
0.04% of portfolio
Propel Bio Management, LLC Los Angeles, CA

1.49M
Shares

$970,314
0.39% of portfolio
Black Rock Inc. New York, NY

676K
Shares

$439,558
0.0% of portfolio

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account